Hear how a single ctDNA blood draw 3 to 9 weeks into immunotherapy may reveal response earlier than imaging in NSCLC, with Valsamo Anagnostou, MD, PhD.
|Videos|October 25, 2013
The Role of the Pathologist During Melanoma Treatment
Author(s)Anthony M. Magliocco, MD
Anthony M. Magliocco, MD, discusses the pathologist’s role when treating a patient with melanoma.
Advertisement
Anthony M. Magliocco, MD, chair of pathology, executive director of esoteric labs at Moffitt Cancer Center, discusses the pathologist’s role when treating a patient with melanoma.
Clinical Pearls
- In addition to the primary practitioner, there is a team of experts that can help guide treatment by providing information on molecular genetics, therapy, and radiation oncology
- A molecular pathologist can help a primary practitioner understand a tumor, the best technology platform to use, how to interpret data, and more
- It is important for a primary practitioner to become familiar with the laboratories they work with in order to better understand the technologies, how they are changing, and what impact they can have on patients
Advertisement
Related to this article
Lauren Banks, MD, PhD, explains early findings from a pilot study of lifileucel in dedifferentiated liposarcoma and undifferentiated pleomorphic sarcoma, including treatment feasibility, safety, and response durability.
Sara Lonardi, MD, discusses the final overall survival analysis of CheckMate-8HW from ESMO 2026 and its implications for first-line MSI-H/dMMR mCRC.
In an interview, David J. Benjamin, MD, explains the findings on gender makeup of NCCN guideline panels he presented at the 2026 ESMO Congress.
New study shows CT-measured body fat, not BMI, links obesity to higher lung cancer risk via immune T-cell changes—hinting at prevention through weight loss.
Recap the 4 late-breaking phase 3 trials from ESMO 2026 Presidential Symposium I in melanoma, bladder cancer, small cell lung cancer, and prostate cancer.
Adding the mRNA-based individualized neoantigen intismeran to pembrolizumab reduced the risk of disease recurrence or death by 42% in melanoma.
Advertisement
Advertisement
Trending on Targeted Onc
1
A New Era in Sarcoma Treatment? Dr Banks on the Potential of TIL Therapy
2
FDA Approves Generic Venetoclax Tablets for CLL/SLL and AML
3
Enzalutamide Fails to Improve Survival in High-Risk Prostate Cancer
4
Neoadjuvant Botensilimab/Balstilimab Shows Activity in Colon Cancer
5